Organon Is Ready To Launch And Makes The Case To Investors
Established Products Will Account For The Majority Of Revenues
Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.
You may also be interested in...
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.
Merck will spinout its mature franchises, including women's health products, into a new company that will have about $6bn-$6.5bn in 2021 revenues and be poised for modest growth.
Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.